Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Neutropenia 1Chemotherapy-Induced Febrile Neutropenia 1Breast Neoplasms 1

Interventions

pegfilgrastim 26Filgrastim 24Cyclophosphamide 8Docetaxel 7Etoposide 6pegylated granulocyte colony-stimulating factor 5Cytarabine 5eflapegrastim 4Granulocyte Colony-Stimulating Factor 4Leucovorin 3Fluorouracil 3Doxorubicin 3Cyclosporine 3Cefepime 3Caspofungin 3Carboplatin 3liposomal amphotericin B 2Vincristine 2Vancomycin 2Topotecan 2Methylprednisolone 2Methotrexate 2Itraconazole 2Irinotecan 2Ifosfamide 2Idarubicin 2Fluconazole 2Daunorubicin 2Cisplatin 2Amikacin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neutropenia × MYL-1401H × Clear all
NCT02467868 2022-02-14

Efficacy and Safety Study With MYL-1401H and Neulasta

Viatris Inc.

Phase 3 Completed
193 enrolled
BreastClassical hematology

Breast Neoplasms, Neutropenia, Chemotherapy-Induced Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡